tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2020 Dec 1;16(12):3061-3073.
doi: 10.1080/21645515.2020.1830683.
SARS-CoV-2 reinfection and implications for vaccine development
Firzan Nainu[SUP] 1 [/SUP], Rufika Shari Abidin[SUP] 2 [/SUP], Muh Akbar Bahar[SUP] 1 [/SUP], Andri Frediansyah[SUP] 3 4 [/SUP], Talha Bin Emran[SUP] 5 [/SUP], Ali A Rabaan[SUP] 6 [/SUP], Kuldeep Dhama[SUP] 7 [/SUP], Harapan Harapan[SUP] 8 9 10 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) pandemic continues to constitute a public health emergency of international concern. Multiple vaccine candidates for COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have entered clinical trials. However, some evidence suggests that patients who have recovered from COVID-19 can be reinfected. For example, in China, two discharged COVID-19 patients who had recovered and fulfilled the discharge criteria for COVID-19 were retested positive to a reverse transcription polymerase chain reaction (RT-PCR) assay for the virus. This finding is critical and could hamper COVID-19 vaccine development. This review offers literature-based evidence of reinfection with SARS-CoV-2, provides explanation for the possibility of SARS-CoV-2 reinfection both from the agent and host points of view, and discusses its implication for COVID-19 vaccine development.
Keywords: SARS-CoV-2; covid-19; reactivation; reinfection; vaccine
. 2020 Dec 1;16(12):3061-3073.
doi: 10.1080/21645515.2020.1830683.
SARS-CoV-2 reinfection and implications for vaccine development
Firzan Nainu[SUP] 1 [/SUP], Rufika Shari Abidin[SUP] 2 [/SUP], Muh Akbar Bahar[SUP] 1 [/SUP], Andri Frediansyah[SUP] 3 4 [/SUP], Talha Bin Emran[SUP] 5 [/SUP], Ali A Rabaan[SUP] 6 [/SUP], Kuldeep Dhama[SUP] 7 [/SUP], Harapan Harapan[SUP] 8 9 10 [/SUP]
Affiliations
- PMID: 33393854
- DOI: 10.1080/21645515.2020.1830683
Abstract
Coronavirus disease 2019 (COVID-19) pandemic continues to constitute a public health emergency of international concern. Multiple vaccine candidates for COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have entered clinical trials. However, some evidence suggests that patients who have recovered from COVID-19 can be reinfected. For example, in China, two discharged COVID-19 patients who had recovered and fulfilled the discharge criteria for COVID-19 were retested positive to a reverse transcription polymerase chain reaction (RT-PCR) assay for the virus. This finding is critical and could hamper COVID-19 vaccine development. This review offers literature-based evidence of reinfection with SARS-CoV-2, provides explanation for the possibility of SARS-CoV-2 reinfection both from the agent and host points of view, and discusses its implication for COVID-19 vaccine development.
Keywords: SARS-CoV-2; covid-19; reactivation; reinfection; vaccine